- Home
- HIG vs TAK Comparison
HIG vs TAK Comparison
Compare HIG & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIG | TAK |
|---|---|---|
| Founded | 1810 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5B | 43.3B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIG | TAK |
|---|---|---|
| Price | $129.33 | $16.16 |
| Analyst Decision | Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $148.13 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 2.6M |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | 1.85% | ★ 3.27% |
| EPS Growth | ★ 22.54 | N/A |
| EPS | ★ 12.22 | 0.14 |
| Revenue | $27,917,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $7.59 | N/A |
| Revenue Next Year | $5.65 | $0.47 |
| P/E Ratio | ★ $10.60 | $226.88 |
| Revenue Growth | ★ 7.03 | N/A |
| 52 Week Low | $105.98 | $12.80 |
| 52 Week High | $140.50 | $16.48 |
Technical Indicators
Market Signals| Indicator | HIG | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 63.86 |
| Support Level | $131.26 | $15.87 |
| Resistance Level | $138.62 | $16.48 |
| Average True Range (ATR) | 1.96 | 0.19 |
| MACD | -1.14 | 0.01 |
| Stochastic Oscillator | 0.40 | 66.00 |
Price Performance
Historical ComparisonAbout HIG Hartford Financial Services Group Inc. (The)
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.